The FDA on February 26, 2018 approved VERZENIO® in combination with an Aromatase Inhibitor, as initial endocrine-based therapy for postmenopausal women with Hormone Receptor (HR)-positive, Human Epidermal growth factor Receptor 2 (HER2)-negative advanced or metastatic breast cancer. VERZENIO® is a product of Eli Lilly and Company.
Other Pages – Bottom Ad
Advertisement
Subscribe
